Increased Risk of Breakthrough Infection among Cytomegalovirus Donor Positive/Recipient Negative Kidney Transplant Recipients Receiving Lower Dose Valganciclovir Prophylaxis

被引：0
|
作者：
Stevens, D. [1 ]
Trofe-Clark, J. [1 ,2 ]
Blumberg, E. [2 ]
Wilck, M. [2 ]
Weikert, B. [2 ]
Goral, S. [2 ]
Bleicher, M. [2 ]
Sawinski, D. [2 ]
Abt, P. [2 ]
Levine, M. [2 ]
Porrett, P. [2 ]
Bloom, R. [2 ]
机构：
[1] Hosp Univ Penn, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2013年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：321 / 321
页数：1
相关论文
共 50 条
  • [41] Delayed graft function and rejection are risk factors for cytomegalovirus breakthrough infection in kidney transplant recipients
    Kleinherenbrink, Wieteke
    Baas, Marije
    Nakhsbandi, Gizal
    Hesselink, Dennis A.
    Roodnat, Joke, I
    de Winter, Brenda C.
    Hilbrands, Luuk
    van Gelder, Teun
    PHARMACOLOGICAL RESEARCH, 2021, 167
  • [42] Randomized trial of preemptive valganciclovir therapy versus valacyclovir prophylaxis for the management of cytomegalovirus infection in kidney transplant recipients.
    Reischig, Tomas
    Jindra, Pavel
    Klaboch, Jan
    Svecova, Miroslava
    Hes, Ondrej
    Treska, Vladislav
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 506 - 506
  • [43] EFFICACY AND SAFETY OF LOW DOSE VERSUS HIGH DOSE VALGANCICLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN INTERMEDIATE RISK KIDNEY TRANSPLANT RECIPIENTS
    Halim, Medhat Abdel
    Al-Otaibi, Torki
    Gheith, Osama
    Adel, Hany
    Mosaad, Ahmed
    Abu-Atteya, Hassaneen
    Zakaria, Zakaria
    Makkeya, Yahia
    Said, Tarek
    Nair, Prasad
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 1568 - 1569
  • [44] Increasing Proportion of High-risk Cytomegalovirus Donor-positive/Recipient-negative Serostatus in Solid Organ Transplant Recipients
    Imlay, Hannah
    Wagener, Marilyn M.
    Vutien, Philip
    Perkins, James
    Singh, Nina
    Limaye, Ajit P.
    TRANSPLANTATION, 2023, 107 (04) : 988 - 993
  • [45] Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis
    Boudreault, A. A.
    Xie, H.
    Rakita, R. M.
    Scott, J. D.
    Davis, C. L.
    Boeckh, M.
    Limaye, A. P.
    TRANSPLANT INFECTIOUS DISEASE, 2011, 13 (03) : 244 - 249
  • [46] Low-Dose Valganciclovir Prophylaxis Against Cytomegalovirus in Intermediate-Risk Liver and Dual-Abdominal Transplant Recipients
    Li, Yihan
    Pluckrose, Dawn M.
    Patolia, Roshani
    Arnouk, Serena
    Dubrovskaya, Yanina
    Papadopoulos, John
    Jonchhe, Srijana
    ANNALS OF PHARMACOTHERAPY, 2025, 59 (01) : 34 - 40
  • [47] Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis
    Paulsen, Grant
    Cumagun, Pia
    Mixon, Emily
    Fowler, Karen
    Feig, Daniel
    Shimamura, Masako
    PEDIATRIC TRANSPLANTATION, 2019, 23 (03)
  • [48] Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients
    Bixby, Alexandra L.
    Fitzgerald, Linda
    Park, Jeong M.
    Kaul, Daniel
    Tischer, Sarah
    TRANSPLANT INFECTIOUS DISEASE, 2021, 23 (05)
  • [49] Management of BK viremia is associated with a lower risk of subsequent cytomegalovirus infection in kidney transplant recipients
    Jorgenson, Margaret R.
    Descourouez, Jillian L.
    Lyu, Beini
    Astor, Brad C.
    Saddler, Christopher M.
    Mandelbrot, Didier A.
    Parajuli, Sandesh
    CLINICAL TRANSPLANTATION, 2020, 34 (03)
  • [50] Increased incidence of late-onset CW disease in high-risk liver transplant recipients receiving valganciclovir prophylaxis
    Shiley, Kevin T.
    Gasink, Leanne B.
    Barton, Todd D.
    Pfeiffenberger, Patrice
    Olthoff, Kim M.
    Blumberg, Emily A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 564 - 564
12345